gms | German Medical Science

11. Jahrestagung 2004 der GAA

Gesellschaft für Arzneimittelforschung und Arzneimittelepidemiologie

30.09. bis 01.10.2004, Jena

Questioning of physicians about their drug prescribing behaviour

Meeting Abstract

Suche in Medline nach

Gesellschaft für Arzneimittelanwendungsforschung und Arzneimittelepidemiologie (GAA) e.V.. 11. Jahrestagung der Gesellschaft für Arzneimittelforschung und Arzneimittelepidemiologie (GAA) e.V.. Jena, 30.09.-01.10.2004. Düsseldorf, Köln: German Medical Science; 2004. Doc04gaa28

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter:

Veröffentlicht: 30. September 2004

© 2004 Kasek et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.




At the beginning of the year 2004 there were changes of drug price ordinance and in non-ethical market (OTC-drugs).


To understand better the range of factors that influence the decision-making process in drug prescribing.

Material and Methods

In February of 2004 it was carried out a written survey among 266 practices of Saxony, selected purposively from all in 2003 contacted practices by pharmacological advisory service of AOK Sachsen. Questionnaire contains 16 questions, among this thirteen closed-ended questions.


The participation rate was 55%. The most frequently cited influences of the prescribing process were physicians personal clinical experiences with drugs and the national prescribing guidelines.

Physicians quality circles were the most frequently used information source to solve difficult therapeutic questions followed by information of pharmaceutical industry and the recommendations of drug commission of the German medical profession. Cost of drugs are also a deciding factor, but not so important.

In case of new drugs we identified three domains that physicians considered in evaluating new drugs: treatment success, side effect profile and cost.

Only 2% of the physicians believe that new drugs have a greater therapeutic impact and prefer these therefore. A problem is the lack of information of physicians about the expenditure situation of their regionally association of SHI-Accredited physicians.


Results of the survey have implications for co-operation between AOK Sachsen and the physicians. The benefit of independent scientific sources of information has to mediate better.

Conflict of interest: The authors have no financial interests to disclose.